Fagoterapia como alternativa no combate às infecções bacterianas multirresistentes: uma revisão integrativa
DOI:
https://doi.org/10.55905/revconv.16n.11-084Keywords:
fagoterapia, multirresistência bacteriana, bacteriófagosAbstract
O aumento da multirresistência bacteriana elencado como uma ameaça global colocou em pauta novas alternativas para o combate de infecções multirresistentes. Os bacteriófagos, partículas capazes de infectar e controlar infecções bacterianas se apresentam como uma possibilidade de enfrentamento a essa grave ameaça. Dessa forma, o uso de fagos como forma de combater infecções multirresistentes têm sido reconsiderado na ciência atual. Assim, a fagoterapia apresenta-se como uma possibilidade futura de tratamento para doenças causadas por agentes bacterianos atualmente de difícil tratamento. O objetivo deste estudo é analisar a eficácia da fagoterapia como alternativa no combate às infecções multirresistentes. A metodologia utilizada foi de revisão integrativa baseada na análise de 12 artigos de revisão sistemática e ensaios clínicos. Os resultados apontaram a fagoterapia segura em todos os estudos e eficaz em 75% dos experimentos. O presente estudo concluiu que a fagoterapia foi eficaz para infecções por K. pneumoniae, A. baumannii, A. xylosoxidans, S. aureus e P. aeruginosa. Por outro lado, estudos com fagos de Myoviridae e Siphoviridae falharam em combater E. coli, Streptococcus.ssp e K. pneumoniae.
References
AL-ANANY, Amany M.; HOOEY, Payton B.; COOK, Jonathan D.; BURROWS, Lori L.; MARTYNIUK, Julia; HYNES, Alexander P.; GERMAN, Greg J.. Phage Therapy in the Management of Urinary Tract Infections: a comprehensive systematic review. Phage, [S.L.], v. 4, n. 3, p. 112-127, 1 set. 2023.
AL-ISHAQ, Raghad Khalid; SKARIAH, Sini; BÜSSELBERG, Dietrich. Bacteriophage Treatment: critical evaluation of its application on world health organization priority pathogens. Viruses, [S.L.], v. 13, n. 1, p. 51, 30 dez. 2020.
ARANAGA, Carlos; PANTOJA, Lady Daniela; MARTÍNEZ, Edgar Andrés; FALCO, Aura. Phage Therapy in the Era of Multidrug Resistance in Bacteria: a systematic review. International Journal Of Molecular Sciences, [S.L.], v. 23, n. 9, p. 4577, 21 abr. 2022.
ASLAM, Saima; COURTWRIGHT, Andrew M.; KOVAL, Christine; LEHMAN, Susan M.; MORALES, Sandra; FURR, Carrie-Lynn Langlais; ROSAS, Francisco; BROWNSTEIN, Michael J.; FACKLER, Joseph R.; SISSON, Brittany M.. Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. American Journal Of Transplantation, [S.L.], v. 19, n. 9, p. 2631-2639, set. 2019.
BAO, Juan; WU, Nannan; ZENG, Yigang; CHEN, Liguang; LI, Linlin; YANG, Lan; ZHANG, Yiyuan; GUO, Mingquan; LI, Lisha; LI, Jie. Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae. Emerging Microbes & Infections, [S.L.], v. 9, n. 1, p. 771-774, 1 jan. 2020.
CANO, Edison J; CAFLISCH, Katherine M; BOLLYKY, Paul L; VAN BELLEGHEM, Jonas D; PATEL, Robin; FACKLER, Joseph; BROWNSTEIN, Michael J; HORNE, Bri’anna; BISWAS, Biswajit; HENRY, Matthew. Phage Therapy for Limb-threatening Prosthetic KneeKlebsiella pneumoniaeInfection: case report and in vitro characterization of anti-biofilm activity. Clinical Infectious Diseases, [S.L.], v. 73, n. 1, p. 144-151, 23 jul. 2020.
CHAN, Benjamin K; TURNER, Paul e; KIM, Samuel; MOJIBIAN, Hamid R; A ELEFTERIADES, John; NARAYAN, Deepak. Phage treatment of an aortic graft infected withPseudomonas aeruginosa. Evolution, Medicine, And Public Health, [S.L.], v. 2018, n. 1, p. 60-66, 1 jan. 2018.
HADDAD, Lynn El; HARB, Cynthia P; A GEBARA, Marc; A STIBICH, Mark; CHEMALY, Roy F. A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans. Clinical Infectious Diseases, [S.L.], v. 69, n. 1, p. 167-178, 3 nov. 2018. Oxford University Press (OUP).
HOYLE, N.; ZHVANIYA, P.; BALARJISHVILI, N.; BOLKVADZE, D.; NADAREISHVILI, L.; NIZHARADZE, D.; WITTMANN, J.; ROHDE, C.; KUTATELADZE, M.. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report. Research In Microbiology, [S.L.], v. 169, n. 9, p. 540-542, nov. 2018.
JAULT, Patrick; LECLERC, Thomas; JENNES, Serge; PIRNAY, Jean Paul; QUE, Yok-Ai; RESCH, Gregory; ROUSSEAU, Anne Françoise; RAVAT, François; CARSIN, Hervé; FLOCH, Ronan Le. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. The Lancet Infectious Diseases, [S.L.], v. 19, n. 1, p. 35-45, jan. 2019.
KILCHER, Samuel; LOESSNER, Martin J.. Engineering Bacteriophages as Versatile Biologics. Trends In Microbiology, [S.L.], v. 27, n. 4, p. 355-367, abr. 2019.
LANGFORD, B. J.; et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, v. 26, n.12, p. 1622–1629, 2020.
LEBEAUX, David; MERABISHVILI, Maia; CAUDRON, Eric; LANNOY, Damien; VAN SIMAEY, Leen; DUYVEJONCK, Hans; GUILLEMAIN, Romain; THUMERELLE, Caroline; PODGLAJEN, Isabelle; COMPAIN, Fabrice. A Case of Phage Therapy against Pandrug-Resistant Achromobacter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient. Viruses, [S.L.], v. 13, n. 1, p. 60, 5 jan. 2021.
LEITNER, Lorenz; UJMAJURIDZE, Aleksandre; CHANISHVILI, Nina; GODERDZISHVILI, Marina; CHKONIA, Irina; RIGVAVA, Sophia; CHKHOTUA, Archil; CHANGASHVILI, Giorgi; MCCALLIN, Shawna; SCHNEIDER, Marc P. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. The Lancet Infectious Diseases, [S.L.], v. 21, n. 3, p. 427-436, mar. 2021.
NADAREISHVILI, L.; HOYLE, N.; NAKAIDZE, N.; NIZHARADZE, D.; KUTATELADZE, M.; BALARJISHVILI, N.; KUTTER, E.; PRUIDZE, N.. Bacteriophage Therapy as a Potential Management Option for Surgical Wound Infections. Phage, [S.L.], v. 1, n. 3, p. 158-165, 1 set. 2020.
OOI, Mian Li; DRILLING, Amanda Jane; MORALES, Sandra; FONG, Stephanie; MORAITIS, Sophia; MACIAS-VALLE, Luis; VREUGDE, Sarah; PSALTIS, Alkis James; WORMALD, Peter-John. Safety and Tolerability of Bacteriophage Therapy for Chronic Rhinosinusitis Due toStaphylococcus aureus. Jama Otolaryngology–Head & Neck Surgery, [S.L.], v. 145, n. 8, p. 723, 1 ago. 2019.
PAYASLIAN, Florencia; GRADASCHI, Victoria; PIURI, Mariana. Genetic manipulation of phages for therapy using BRED. Current Opinion In Biotechnology, [S.L.], v. 68, p. 8-14, abr. 2021.
QIN, Jinhong; WU, Nannan; BAO, Juan; SHI, Xin; OU, Hongyu; YE, Shanke; ZHAO, Wei; WEI, Zhenquan; CAI, Jinfeng; LI, Lisha. Heterogeneous Klebsiella pneumoniae Co-infections Complicate Personalized Bacteriophage Therapy. Frontiers In Cellular And Infection Microbiology, [S.L.], v. 10, n. 5, p. 1-14, 25 jan. 2021.
SCHOOLEY, Robert T.; BISWAS, Biswajit; GILL, Jason J.; HERNANDEZ-MORALES, Adriana; LANCASTER, Jacob; LESSOR, Lauren; BARR, Jeremy J.; REED, Sharon L.; ROHWER, Forest; BENLER, Sean. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrobial Agents And Chemotherapy, [S.L.], v. 61, n. 10, p. 123-143, out. 2017.
SINHA, Avni; ENIYAN, Kandasamy; MANOHAR, Prasanth; RAMESH, Nachimuthu; BAJPAI, Urmi. Characterization and genome analysis of B1 sub-cluster mycobacteriophage PDRPxv. Virus Research, [S.L.], v. 279, p. 197884, abr. 2020.
STACEY, Helen J.; SOIR, Steven de; JONES, Joshua D.. The Safety and Efficacy of Phage Therapy: a systematic review of clinical and safety trials. Antibiotics, [S.L.], v. 11, n. 10, p. 1340, 30 set. 2022.
TAN, Xin; CHEN, Huaisheng; ZHANG, Min; ZHAO, Ying; JIANG, Yichun; LIU, Xueyan; HUANG, Wei; MA, Yingfei. Clinical Experience of Personalized Phage Therapy Against Carbapenem-Resistant Acinetobacter baumannii Lung Infection in a Patient With Chronic Obstructive Pulmonary Disease. Frontiers In Cellular And Infection Microbiology, [S.L.], v. 11, p. 234-241, 26 fev. 2021.
UKUHOR, Hyacinth O.. The interrelationships between antimicrobial resistance, COVID-19, past, and future pandemics. Journal Of Infection And Public Health, [S.L.], v. 14, n. 1, p. 53-60, jan. 2021.
UYTTEBROEK, Saartje; CHEN, Baixing; ONSEA, Jolien; RUYTHOOREN, Fred; DEBAVEYE, Yves; DEVOLDER, David; SPRIET, Isabel; DEPYPERE, Melissa; WAGEMANS, Jeroen; LAVIGNE, Rob. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. The Lancet Infectious Diseases, [S.L.], v. 22, n. 8, p. 1-14, 22 ago. 2022.
WORTELBOER, Koen; JONGE, Patrick A. de; SCHEITHAUER, Torsten P. M.; ATTAYE, Ilias; KEMPER, E. Marleen; NIEUWDORP, Max; HERREMA, Hilde. Phage-microbe dynamics after sterile faecal filtrate transplantation in individuals with metabolic syndrome: a double-blind, randomised, placebo-controlled clinical trial assessing efficacy and safety. Nature Communications, [S.L.], v. 14, n. 1, p. 3-5, 12 set. 2023.
WU, Nannan; DAI, Jia; GUO, Mingquan; LI, Jianhui; ZHOU, Xin; LI, Feng; GAO, Yuan; QU, Hongping; LU, Hongzhou; JIN, Jing. Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients. Emerging Microbes & Infections, [S.L.], v. 10, n. 1, p. 612-618, 1 jan. 2021.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 CONTRIBUCIONES A LAS CIENCIAS SOCIALES

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.